查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1490317

寡核甘酸合成市場（第三版）：產業趨勢與全球預測（-2035）-依應用領域、合成產品類型、合成寡核甘酸類型、業務規模、治療領域和最終用戶，依公司規模

Oligonucleotide Synthesis Market (3rd Edition): Industry Trends and Global Forecasts, Till 2035 - Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, Therapeutic Area, End-Users
出版日期: | 出版商: Roots Analysis | 英文 325 Pages | 商品交期: 最快1-2個工作天內

價格

寡核甘酸合成市場規模預計到 2024 年將達到 48 億美元，並預計在 2024-2035 年預測期內複合年增長率為 9.9%。

寡核甘酸，通常稱為寡核甘酸，是 DNA 或 RNA 分子的短單股片段。每條寡核甘酸鏈通常由 10 至 50 個核甘酸組成，由一個磷酸基、一個醣分子（DNA 中的脫氧核糖、RNA 中的核糖）和一個氮鹼基組成。氮鹼基各不相同；DNA 包括腺嘌呤(A)、胞嘧啶(C)、鳥嘌呤(G) 和胸腺嘧啶(T)，RNA 包括腺嘌呤(A)、胞嘧啶(C)、鳥嘌呤( G) 和尿嘧啶(U) ）。這些分子在基因檢測、分子分析、人工基因合成和聚合□鍊式反應（PCR）等各種分析方法中發揮著至關重要的作用。隨著第一個反義寡核甘酸藥物 Vitravene 的批准，寡核甘酸的用途已從治療擴展到研究和診斷。由於寡核甘酸的獨特性質，例如高標靶特異性和優異的藥物動力學特徵，大量臨床前和臨床研究強調了寡核甘酸作為安全有效治療藥物的潛力。

目前，全球已有超過 15 種基於寡核甘酸的治療方法獲得批准。最近的例子包括 Amvuttra (2022)、AMONDYS 45 (2021)、Leqvio (2021) 和 Oxlumo (2020)。此外，還有大約 300 項臨床研究調查了 14 個治療領域超過 102 種不同適應症的大約 80 種寡核甘酸，針對 66 個不同基因。寡核甘酸主要使用化學合成方法製造，例如亞磷□胺合成和固相合成，但這些方法面臨諸如開發時間延長、純化問題和監管合規性問題等課題。因此，寡核甘酸合成市場的許多研究人員和開發人員選擇將其製造外包給具有必要專業知識和能力的合約服務提供者。此外，由於寡核甘酸在 COVID-19 檢測試劑盒中的廣泛使用，全球對寡核甘酸的需求激增，尤其是在 COVID-19 大流行之後。因此，合約服務提供者正在擴展其能力和能力，以滿足這種不斷增長的需求。此外，不斷增加的基於寡核甘酸的藥物、有希望的臨床試驗結果以及該領域的廣泛研究活動預計將在可預見的未來為定制/合約服務提供者創造利潤豐厚的成長機會。

本報告考察了全球寡核甘酸合成市場，並依應用領域、合成產品類型、合成的寡核甘酸類型、業務規模、治療領域和最終用戶以及公司趨勢提供了市場概述。的公司的規模和地區以及概況。

目錄

第一章前言

第二章研究方法

第 3 章經濟與其他專案特定考量

第 4 章執行摘要

第 5 章簡介

  • 章節概述
  • 寡核甘酸的結構
  • 寡核甘酸的型別
  • 寡核甘酸生產
  • 寡核甘酸製造外包
  • 未來前景

第六章市場狀況

  • 章節概述
  • 寡核甘酸合成供應商：市場情勢

第七章企業競爭力分析

  • 章節概述
  • 假設和主要參數
  • 調查方法
  • 寡核甘酸合成提供者：企業競爭力分析

第八章公司簡介

第 9 章製造與採購的決策架構

  • 章節概述
  • 假設和主要參數
  • 寡核甘酸合成：自製還是外購決策的框架
  • 結論

第十章臨床試驗分析

  • 章節概述
  • 範圍與研究方法
  • 寡核甘酸療法：臨床試驗分析

第 11 章夥伴關係與協作

  • 章節概述
  • 合作夥伴模式
  • 寡核甘酸合成：夥伴關係與協作

第 12 章近期擴展

第十三章主要藥廠的舉措

第14章能力分析

第十五章需求分析

第16章市場影響分析

  • 章節概述
  • 市場驅動因素
  • 市場限制
  • 市場機會
  • 市場課題
  • 結論

第十七章全球寡核甘酸合成市場

  • 章節概述
  • 主要假設與研究方法
  • 全球寡核甘酸合成市場、過去趨勢（2018-2023）與未來預測（2024-2035）
  • 主要市場細分

第十八章寡核甘酸合成市場，依應用領域

第十九章寡核甘酸合成市場，依合成產品類型

第20章寡核甘酸合成市場，依寡核甘酸合成類型

第 21 章寡核甘酸合成市場，依業務規模劃分

第 22 章寡核甘酸合成市場，依治療領域劃分

第 23 章寡核甘酸合成市場，依最終使用者劃分

第 24 章寡核甘酸合成市場，依公司規模劃分

第25章寡核甘酸合成市場：依主要地區

第 26 章高階主管見解

第27章結論

  • 章節概述

第 28 章附錄一：表格資料

第 29 章附錄二：公司與組織名單

Product Code: RA100300

Oligonucleotide Synthesis Market (3rd Edition): Industry Trends and Global Forecasts, Till 2035 - Application Area (Research and Diagnostics, and Therapeutics), Type of Product Synthesized (Active Pharmaceutical Ingredients and Finished Dosage Forms), Type of Oligonucleotide Synthesized (Antisense, DNA, siRNA and Other Oligonucleotides), Scale of Operation (Clinical and Commercial), Therapeutic Area (Cardiovascular Disorders, Genetic Disorders, Liver Disorders, Rare Diseases, and Other Disorders), End-Users (Pharmaceutical / Biopharmaceutical Companies, Academic and Research Institutes, and Hospitals), Company Size (Small, Mid-sized, and Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

The Oligonucleotide Synthesis Market is valued at USD 4.8 billion in 2024 growing at a CAGR of 9.9% during the forecast period 2024-2035.

Oligonucleotides, commonly referred to as oligos, are short single-stranded segments of DNA or RNA molecules. Typically composed of 10-50 nucleotides, each oligonucleotide chain consists of a phosphate group, a sugar molecule (deoxyribose in DNA and ribose in RNA), and a nitrogenous base. The nitrogenous base can vary, with DNA containing adenine (A), cytosine (C), guanine (G), and thymine (T), while RNA includes adenine (A), cytosine (C), guanine (G), and uracil (U). These molecules play pivotal roles in genetic testing, molecular analysis, and various analytical procedures such as artificial gene synthesis and polymerase chain reactions (PCR). The approval of the first antisense oligonucleotide drug, Vitravene, has significantly expanded the applications of oligonucleotides beyond therapeutics, into research and diagnostics. Numerous preclinical and clinical studies have highlighted the potential of oligonucleotides as safe and effective treatment modalities, thanks to their unique characteristics like high target specificity and superior pharmacokinetic profiles.

Currently, more than 15 oligonucleotide-based therapies have received global approval. Recent examples include Amvuttra (2022), AMONDYS 45 (2021), Leqvio (2021), and Oxlumo (2020). Additionally, there are nearly 300 clinical studies investigating approximately 80 oligonucleotides for over 102 different indications across 14 therapeutic areas, targeting 66 different genes. Oligonucleotides are primarily manufactured using chemical synthesis methods like phosphoramidite synthesis and solid-phase synthesis, although these approaches pose challenges such as extended development timelines, purification issues, and regulatory compliance concerns. Consequently, many researchers and developers in the oligonucleotide synthesis market opt to outsource manufacturing to contract service providers with the requisite expertise and capabilities. Moreover, the global demand for oligonucleotides has surged, particularly post the COVID-19 pandemic, due to their widespread use in COVID-19 testing kits. Consequently, contract service providers are expanding their capacities and capabilities to meet this rising demand. Additionally, the growing pipeline of oligonucleotide-based drugs, promising clinical trial outcomes, and extensive research activities in the field are expected to create lucrative growth opportunities for custom/contract service providers in the foreseeable future.

Key Market Segments

Application Area

  • Research and Diagnostics
  • Therapeutics

Type of Product Synthesized

  • Active Pharmaceutical Ingredients
  • Finished Dosage Forms

Type of Oligonucleotide Synthesized

  • Antisense

DNA

  • siRNA
  • Other Oligonucleotides

Scale of Operation

  • Clinical
  • Commercial

Therapeutic Area

  • Cardiovascular Disorders
  • Genetic Disorders
  • Liver Disorders
  • Rare Diseases
  • Other Disorders

End-users

  • Pharmaceutical/Biopharmaceutical Companies
  • Academic And Research Institutes
  • Hospitals

Company Size

  • Small
  • Mid-sized
  • Large and Very Large

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Research Coverage:

  • This chapter provides a comprehensive overview of oligonucleotides and their various types. It delves into the different steps involved in custom oligonucleotide synthesis, as well as the processes of chemical modification and purification of oligonucleotides. Additionally, the chapter discusses the challenges associated with oligonucleotide manufacturing, including regulatory hurdles and technical complexities, leading to the growing trend of outsourcing manufacturing operations. Furthermore, it examines the key growth drivers and barriers in oligonucleotide manufacturing, along with upcoming trends in the field. Through this discussion, readers gain a thorough understanding of the oligonucleotide manufacturing landscape and its evolving dynamics.
  • This chapter conducts a comprehensive evaluation of oligonucleotide synthesis providers, considering various crucial parameters, such as the year of establishment, company size, location of headquarters, location of oligonucleotide synthesis facilities, and scale of operation. Additionally, the assessment covers the types of oligonucleotides synthesized, such as antisense oligonucleotides, aptamers, DNA oligonucleotides, oligonucleotide probes, primers, RNA oligonucleotides, and others. It also examines the type of products synthesized, including oligonucleotide APIs and finished dosage forms/drug products, as well as the application areas such as research, diagnostics, and therapeutics. Furthermore, the evaluation considers the additional services offered by these providers, encompassing process development/method validation, analytical testing, custom synthesis, sequencing, modification, purification, fill-finish, quality assurance and control, and regulatory support. Through this thorough assessment, readers gain insights into the capabilities and offerings of various oligonucleotide synthesis providers, aiding informed decision-making in selecting suitable partners or suppliers within the industry.
  • This chapter undertakes an extensive competitiveness analysis of oligonucleotide synthesis providers, focusing on several key parameters, such as supplier strength, which is evaluated based on years of experience in the industry. Additionally, service strength is assessed, considering factors such as the scale of operation, types of oligonucleotides synthesized, application areas served, types of products synthesized, and the range of additional services offered. Moreover, the number of oligonucleotide synthesis facilities operated by each provider is considered a crucial factor in evaluating their competitiveness. Through this detailed analysis, readers gain insights into the competitive positioning of oligonucleotide synthesis providers, aiding informed decision-making in selecting suitable partners or suppliers within the industry.
  • Detailed company profiles of prominent players (shortlisted based on our proprietary criteria) engaged in offering oligonucleotide synthesis services. Each profile features a brief overview of the company (including information on year of establishment, location of headquarters, number of employees and leadership team), financial information (if available), service portfolio, recent developments and an informed future outlook.
  • This section presents an insightful make-versus-buy framework, examining the key indicators and factors affecting the developers' decision-making whether to outsource oligonucleotide manufacturing operations or set-up in-house capabilities. Through this framework, various critical factors such as cost analysis, technological expertise, regulatory compliance, scalability, timelines, and strategic alignment are examined in detail. By considering these factors, sponsors and developers can make informed decisions that align with their organizational goals, resources, and long-term strategies.
  • Comprehensive analysis of completed, ongoing, and planned clinical studies evaluating various oligonucleotide therapeutics, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor, most active industry players (in terms of number of trials conducted), study design, therapeutic area and key geographical regions.
  • Elaborate assessment of the partnerships inked between stakeholders in this industry, since 2014, based on several parameters, such as year of partnership, type of partnership, type of oligonucleotide, therapeutic area, application area and the most active players (in terms of the number of partnerships signed). It also provides for the regional distribution of the companies involved in these agreements.
  • Comprehensive assessment of expansion initiatives undertaken by oligonucleotide synthesis providers, during the period, since 2015, along with information on several relevant parameters, such as year of expansion, type of expansion, scale of operation, application area, amount invested, area of facility and location of expanded facility.
  • Comprehensive review of the various oligonucleotide-focused manufacturing initiatives undertaken by top 13 big pharma players (shortlisted on the basis of 2022 revenues), highlighting trends across various parameters, such as number of initiatives, year of initiative, type of initiative, type of initiative, scale of operation, type of oligonucleotide manufactured, and amount invested.
  • Elaborate insight on the overall installed capacity for manufacturing of oligonucleotides, based on information reported by various industry stakeholders in the public domain. The analysis highlights the distribution of the available capacity based on the company size (small, mid-sized, and large and very large firms) and key geographical regions (North America, Europe and, Asia-Pacific and Rest of the World).
  • This chapter provides an informed estimate of the annual clinical demand for oligonucleotide therapeutics, considering the target patient population in ongoing and planned clinical trials sponsored by both industry and non-industry players. Additionally, we estimate the commercial demand for oligonucleotides by analyzing the top 12 oligonucleotide-based therapies and phase III drugs. This estimation takes into account various relevant parameters such as the target patient population, dosing frequency, and dose strength of the aforementioned products. Through this analysis, readers gain insights into the expected clinical and commercial demand for oligonucleotide therapeutics, aiding in strategic planning and decision-making within the industry.
  • Comprehensive assessment of the factors that can impact the growth of oligonucleotide synthesis services market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • This section presents a detailed forecast of the oligonucleotide synthesis market to estimate both the current market size and future opportunities over the next 11 years. Leveraging multiple parameters and anticipated adoption trends, we have provided an informed estimate of the market size during the forecast period from 2024 to 2035. These estimations are further validated through primary research and analysis to ensure accuracy and reliability. Through this forecast, readers gain insights into the expected growth trajectory and potential opportunities within the oligonucleotide synthesis market, aiding in strategic planning and decision-making for stakeholders in the industry.
  • Comprehensive projections of the current and future opportunity within the oligo synthesis market across different application areas, such as research and diagnostics, and therapeutics.
  • Elaborate projections of the current and future opportunity within the oligo synthesis market across different types of product synthesized, such as active pharmaceutical ingredients and finished dosage forms.
  • Comprehensive projections of the current and future oligo synthesis market across different types of oligonucleotide synthesized, such as antisense, DNA, siRNA and other oligonucleotides.
  • Detailed projections of the current and future opportunity within the oligonucleotide synthesis market across different scales of operation, such as clinical and commercial.
  • Detailed projections of the current and future opportunity within the oligonucleotide synthesis industry across different therapeutic areas, such as cardiovascular disorders, genetic disorders, liver disorders, rare diseases, and other disorders.
  • Detailed projections of the current and future opportunity within the field of oligonucleotide synthesis across different end-users, such as pharmaceutical / biopharmaceutical companies, academic and research institutes, and hospitals.
  • Detailed projections of the current and future opportunity within the field of oligonucleotide synthesis across different company sizes, such as small, mid-sized, and large and very large.
  • Detailed projections of the current and future opportunity within the oligonucleotide synthesis market across key geographical regions, such as North America, Europe, Asia-Pacific and Rest of the World.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Oligonucleotide Synthesis Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • Agilent Technologies
  • Ajinomoto Bio-Pharma Services
  • CordenPharma
  • Creative Biolabs
  • Ella Biotech
  • Eurofins Genomics
  • Future synthesis
  • Integrated DNA Technologies
  • Kaneka Eurogentec
  • LGC Biosearch Technologies
  • Merck
  • Microsynth
  • Nitto Avecia
  • Ribo Biotechnology
  • STA Pharmaceutical / Wuxi STA
  • Sumitomo Chemical
  • Thermo Fisher Scientific
  • TriLink Biotechnologies

TABLE OF CONTENTS

Table Of Contents

1. PREFACE

  • 1.1. Oligonucleotide Synthesis Market Overview
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

  • 4.1. Chapter Overview

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Oligonucleotide Structure
  • 5.3. Types of Oligonucleotides
    • 5.3.1. Antisense Oligonucleotides
    • 5.3.2. Aptamers
    • 5.3.3. miRNA
    • 5.3.4. shRNA
    • 5.3.5. siRNA
    • 5.3.6. Other Oligonucleotides
  • 5.4. Manufacturing of Oligonucleotides
    • 5.4.1. Synthesis of Oligonucleotides
      • 5.4.1.1. Process Development / Validation
      • 5.4.1.2. Analytical Testing
      • 5.4.1.3. Quality Control and Quality Assurance
    • 5.4.2. Modification of Oligonucleotides
      • 5.4.2.1. Backbone Modification
      • 5.4.2.2. Sugar Ring Modification
    • 5.4.3. Purification of Oligonucleotides
      • 5.4.3.1. Cartridge Purification
      • 5.4.3.2. Desalting
      • 5.4.3.3. High Performance Liquid Chromatography
      • 5.4.3.4. Polyacrylamide Gel Electrophoresis
    • 5.4.4 Formulation of Oligonucleotides
  • 5.5. Outsourcing Oligonucleotide Manufacturing
    • 5.5.1. Need for Outsourcing
    • 5.5.2. Advantages of Outsourcing Manufacturing Operations
  • 5.6. Future Perspectives

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Oligonucleotide Synthesis Providers: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by Company Size and Location of Headquarters
    • 6.2.5. Analysis by Location of Oligonucleotide Synthesis Facilities
    • 6.2.6. Analysis by Scale of Operation
    • 6.2.7. Analysis by Type of Oligonucleotide Synthesized
    • 6.2.8. Analysis by Type of Oligonucleotide Product Synthesized
    • 6.2.9. Analysis by Application Area
    • 6.2.10. Analysis by Type of Additional Service Offered

7. COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Assumptions and Key Parameters
  • 7.3. Methodology
  • 7.4. Oligonucleotide Synthesis Providers: Company Competitiveness Analysis
    • 7.4.1. Oligonucleotide Synthesis Providers Based in North America
    • 7.4.2. Oligonucleotide Synthesis Providers Based in Europe
    • 7.4.3. Oligonucleotide Synthesis Providers Based in Asia- Pacific and Rest of the World

8. COMPANY PROFILES

  • 8.1. Chapter Overview
  • 8.2. Detailed Company Profiles of Leading Service Providers
    • 8.2.1. Agilent Technologies
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Information
      • 8.2.1.3. Service Portfolio
      • 8.2.1.4. Recent Developments and Future Outlook
    • 8.2.2. Ajinomoto Bio-Pharma Services
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Information
      • 8.2.2.3. Service Portfolio
      • 8.2.2.4. Recent Developments and Future Outlook
    • 8.2.3. CordenPharma
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Service Portfolio
      • 8.2.3.3. Recent Developments and Future Outlook
    • 8.2.4. Integrated DNA Technologies
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Service Portfolio
      • 8.2.4.3. Recent Developments and Future Outlook
    • 8.2.5. Kaneka Eurogentec
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Information
      • 8.2.5.3. Service Portfolio
      • 8.2.5.4. Recent Developments and Future Outlook
    • 8.2.6. LGC Biosearch Technologies
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Information
      • 8.2.6.3. Service Portfolio
      • 8.2.6.4. Recent Developments and Future Outlook
    • 8.2.7. Microsynth
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Service Portfolio
      • 8.2.7.3. Recent Developments and Future Outlook
    • 8.2.8. Merck
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Information
      • 8.2.8.3. Service Portfolio
      • 8.2.8.4. Recent Developments and Future Outlook
    • 8.2.9. Nitto Avecia
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Information
      • 8.2.9.3. Service Portfolio
      • 8.2.9.4. Recent Developments and Future Outlook
    • 8.2.10. Thermo Fisher Scientific
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Information
      • 8.2.10.3. Service Portfolio
      • 8.2.10.4. Recent Developments and Future Outlook
    • 8.2.11. TriLink BioTechnologies
      • 8.2.11.1. Company Overview
      • 8.2.11.2. Service Portfolio
      • 8.2.11.3. Recent Developments and Future Outlook
  • 8.3. Short Company Profiles of Leading Service Providers
    • 8.3.1. Creative Biolabs
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Service Portfolio
    • 8.3.2. Ella Biotech
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Service Portfolio
    • 8.3.3. Eurofins Genomics
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Service Portfolio
    • 8.3.4. Future Synthesis
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Service Portfolio
    • 8.3.5. Ribo Biotechnology
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Service Portfolio
    • 8.3.6. STA Pharmaceutical
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Service Portfolio
    • 8.3.7. Sumitomo Chemical
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Service Portfolio

9. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Key Parameters
  • 9.3. Oligonucleotide Synthesis: Make versus Buy Decision Making Framework
    • 9.3.1. Scenario 1
    • 9.3.2. Scenario 2
    • 9.3.3. Scenario 3
    • 9.3.4. Scenario 4
  • 9.4. Concluding Remarks

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Oligonucleotide Therapeutics: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Status
    • 10.3.3. Analysis by Trial Registration Year and Trial Status
    • 10.3.4. Analysis by Trial Phase
    • 10.3.5. Analysis by Trial Registration Year and Trial Phase
    • 10.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
    • 10.3.7. Analysis of Enrolled Patient Population by Trial Phase
    • 10.3.8. Analysis by Type of Oligonucleotide
    • 10.3.9. Analysis by Therapeutic Area
    • 10.3.10. Analysis by Study Design
    • 10.3.11. Analysis by Type of Sponsor
    • 10.3.12. Most Active Players: Analysis by Number of Registered Trials
    • 10.3.13. Analysis of Number of Registered Trials by Geography
    • 10.3.14. Analysis of Number of Registered Trials by Trial Status and Geography
    • 10.3.15. Analysis of Enrolled Patient Population by Geography
    • 10.3.16. Analysis of Enrolled Patient Population by Trial Status and Geography

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. Oligonucleotide Synthesis: Partnerships and Collaborations
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Analysis by Year and Type of Partnership
    • 11.3.4. Analysis by Type of Oligonucleotide
    • 11.3.5. Analysis by Therapeutic Area
    • 11.3.6. Analysis by Application Area
    • 11.3.7. Most Active Players: Analysis by Number of Partnerships
    • 11.3.8. Analysis by Geography
      • 11.3.8.1. Intracontinental and Intercontinental Agreements
      • 11.3.8.2. Local and International Agreements

12. RECENT EXPANSIONS

  • 12.1. Chapter Overview
  • 12.2. Type of Expansion
  • 12.3. Oligonucleotide Synthesis: Recent Expansions
    • 12.3.1. Analysis by Year of Expansion
    • 12.3.2. Analysis by Type of Expansion
    • 12.3.3. Analysis by Year and Type of Expansion
    • 12.3.4. Analysis by Location of Expanded Facility
    • 12.3.5. Analysis by Type of Expansion and Location of Expanded Facility
    • 12.3.6. Analysis by Area of Expanded Facility
    • 12.3.7. Analysis by Scale of Operation
    • 12.3.8. Analysis by Amount Invested
    • 12.3.9. Most Active Players: Analysis by Number of Expansions

13. BIG PHARMA INITIATIVES

  • 13.1. Chapter Overview
  • 13.2. Oligonucleotide Related Initiatives by Big Pharmaceutical Players
    • 13.2.1. Analysis by Number of Initiatives
    • 13.2.2. Analysis by Year of Initiative
    • 13.2.3. Analysis by Type of Initiative
      • 13.2.3.1. Analysis by Type of Partnership
      • 13.2.3.2. Analysis by Type of Expansion
    • 13.2.4. Analysis by Year and Type of Initiative
    • 13.2.5. Analysis by Scale of Operation
    • 13.2.6. Analysis by Type of Oligonucleotide
    • 13.2.7. Analysis by Amount Invested

14. CAPACITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Oligonucleotide Synthesis: Global Installed Capacity
    • 14.3.1. Analysis by Company Size
    • 14.3.2. Analysis by Geography
      • 14.3.2.1. Analysis of Oligonucleotide Synthesis Capacity in North America
      • 14.3.2.2. Analysis of Oligonucleotide Synthesis Capacity in Europe
      • 14.3.2.3. Analysis of Oligonucleotide Synthesis Capacity in Asia-Pacific and Rest of the World
    • 14.3.3. Concluding Remarks

15. DEMAND ANALYSIS

  • 15.1 Chapter Overview
  • 15.2. Assumptions and Methodology
  • 15.3. Overall Demand for Oligonucleotides
  • 15.4. Global Clinical Demand for Oligonucleotides
    • 15.4.1. Analysis by Type of Oligonucleotide
    • 15.4.2. Analysis by Therapeutic Area
    • 15.4.3. Analysis by Geography
  • 15.5. Global Commercial Demand for Oligonucleotides
    • 15.5.1. Analysis by Type of Oligonucleotide
    • 15.5.2. Analysis by Therapeutic Area
    • 15.5.3. Analysis by Geography

16. MARKET IMPACT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Market Drivers
  • 16.3. Market Restraints
  • 16.4. Market Opportunities
  • 16.5. Market Challenges
  • 16.6. Conclusion

17. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Global Oligonucleotide Synthesis Market, Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 17.3.1. Scenario Analysis
      • 17.3.1.1. Conservative Scenario
      • 17.3.1.2. Optimistic Scenario
  • 17.4. Key Market Segmentations

18. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION AREA

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Oligonucleotide Synthesis Market: Distribution by Application Area, 2018, 2024 and 2035
    • 18.3.1. Research and Diagnostics: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 18.3.2. Therapeutics: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 18.4. Data Triangulation and Validation

19. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE OF PRODUCT SYNTHESIZED

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Oligonucleotide Synthesis Market: Distribution by Type of Product Synthesized, 2018, 2024 and 2035
    • 19.3.1. Active Pharmaceutical Ingredients: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 19.3.2. Finished Dosage Forms: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 19.4. Data Triangulation and Validation

20. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE OF OLIGONUCLEOTIDE SYNTHESIZED

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Oligonucleotide Synthesis Market: Distribution by Type of Oligonucleotide Synthesized, 2018, 2024 and 2035
    • 20.3.1. Antisense Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 20.3.2. DNA Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 20.3.3. siRNA Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 20.3.4. Other Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 20.4. Data Triangulation and Validation

21. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY SCALE OF OPERATION

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Oligonucleotide Synthesis Market: Distribution by Scale of Operation, 2018, 2024 and 2035
    • 21.3.1. Clinical Scale of Operation: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 21.3.2. Commercial Scale of Operation: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 21.4. Data Triangulation and Validation

22. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY THERAPEUTIC AREA

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Oligonucleotide Synthesis Market: Distribution Therapeutic Area, 2018, 2024 and 2035
    • 22.3.1. Cardiovascular Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 22.3.2. Genetic Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 22.3.3. Liver Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 22.3.4. Rare Diseases: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 22.3.5. Other Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 22.4. Data Triangulation and Validation

23. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END-USERS

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. Oligonucleotide Synthesis Market: Distribution by End-users, 2018, 2024 and 2035
    • 23.3.1. Pharmaceutical / Biopharmaceutical Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 23.3.2. Academic and Research Institutes: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 23.3.3. Hospitals: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 23.4. Data Triangulation and Validation

24. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COMPANY SIZE

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. Oligonucleotide Synthesis Market: Distribution by Company Size, 2018, 2024 and 2035
    • 24.3.1. Small Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 24.3.2. Mid-sized Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 24.3.3. Large and Very Large Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 24.4. Data Triangulation and Validation

25. OLIGONUCLEOTIDE SYNTHESIS MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. Oligonucleotide Synthesis Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
    • 25.3.1. North America: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.1.1. US: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.1.2. Canada: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 25.3.2. Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.2.1. Switzerland: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.2.2. Germany: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.2.3. Belgium: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.2.4. Rest of Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 25.3.3. Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.3.1. China: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.3.2. South Korea: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.3.3. Japan: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.3.4. India: Historical Trends (2018-2023) and Future Estimates (2024-2035)
      • 25.3.3.5. Rest of Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
    • 25.3.4. Rest of the World: Historical Trends (2018-2023) and Future Estimates (2024-2035)
  • 25.4. Data Triangulation and Validation

26. EXECUTIVE INSIGHTS

  • 26.1. Chapter Overview
  • 26.2. BianoGMP
    • 26.2.1. Company Snapshot
    • 26.2.2. Interview Transcript
  • 26.3. Hanugen Therapeutics
    • 26.3.1. Company Snapshot
    • 26.3.2. Interview Transcript
  • 26.4. IBA Life Sciences
    • 26.4.1. Company Snapshot
    • 26.4.2 Interview Transcript
  • 26.5. Axolabs
    • 26.5.1. Company Snapshot
    • 26.5.2. Interview Transcript
  • 26.6. SBS Genetech
    • 26.6.1. Company Snapshot
    • 26.6.2. Interview Transcript
  • 26.7. Aptagen
    • 26.7.1. Company Snapshot
    • 26.7.2. Interview Transcript
  • 26.8. Invitek Diagnostics
    • 26.8.1. Company Snapshot
    • 26.8.2. Interview Transcript

27. CONCLUDING REMARKS

  • 27.1. Chapter Overview

28. APPENDIX I: TABULATED DATA

29. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List of Tables

  • Table 6.1. List of Oligonucleotide Synthesis Providers
  • Table 6.2. Oligonucleotide Synthesis Providers: Information on Scale of Operation and Type of Oligonucleotide Synthesized
  • Table 6.3. Oligonucleotide Synthesis Providers: Information on Type of Product Synthesized and Application
  • Table 6.4. Oligonucleotide Synthesis Providers: Information on Type of Additional Services Offered
  • Table 8.1. Oligonucleotide Synthesis: List of Service Providers Profiled
  • Table 8.2. Agilent Technologies: Company Snapshot
  • Table 8.3. Agilent Technologies: Service Portfolio
  • Table 8.4. Agilent Technologies: Recent Developments and Future Outlook
  • Table 8.5. Ajinomoto Bio-Pharma Services: Company Snapshot
  • Table 8.6. Ajinomoto Bio-Pharma Services: Service Portfolio
  • Table 8.7. Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
  • Table 8.8. CordenPharma: Company Snapshot
  • Table 8.9. CordenPharma: Service Portfolio
  • Table 8.10. CordenPharma: Recent Developments and Future Outlook
  • Table 8.11. Integrated DNA Technologies: Company Snapshot
  • Table 8.12. Integrated DNA Technologies: Service Portfolio
  • Table 8.13. Integrated DNA Technologies: Recent Developments and Future Outlook
  • Table 8.14. Kaneka Eurogentec: Company Snapshot
  • Table 8.15. Kaneka Eurogentec: Service Portfolio
  • Table 8.16. LGC Biosearch Technologies: Company Snapshot
  • Table 8.17. LGC Bioresearch Technologies: Service Portfolio
  • Table 8.18. LGC Biosearch Technologies: Recent Developments and Future Outlook
  • Table 8.19. Microsynth: Company Snapshot
  • Table 8.20. Microsynth: Service Portfolio
  • Table 8.21. Merck: Company Snapshot
  • Table 8.22. Merck: Service Portfolio
  • Table 8.23. Merck: Recent Developments and Future Outlook
  • Table 8.24. Nitto Avecia: Company Snapshot
  • Table 8.25. Nitto Avecia: Service Portfolio
  • Table 8.26. Nitto Avecia: Recent Developments and Future Outlook
  • Table 8.27. Thermo Fisher Scientific: Company Snapshot
  • Table 8.28. Thermo Fisher Scientific: Service Portfolio
  • Table 8.29. Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 8.30. TriLink BioTechnologies: Company Snapshot
  • Table 8.31. TriLink BioTechnologies: Service Portfolio
  • Table 8.32. Creative Biolabs: Company Snapshot
  • Table 8.33. Creative Biolabs: Service Portfolio
  • Table 8.34. Ella Biotech: Company Snapshot
  • Table 8.35. Ella Biotech: Service Portfolio
  • Table 8.36. Eurofins Genomics: Company Snapshot
  • Table 8.37. Eurofins Genomics: Service Portfolio
  • Table 8.38. Future Synthesis: Company Snapshot
  • Table 8.39. Future Synthesis: Service Portfolio
  • Table 8.40. Ribo Biotechnology: Company Snapshot
  • Table 8.41. Ribo Biotechnology: Service Portfolio
  • Table 8.42. STA Pharmaceutical: Company Snapshot
  • Table 8.43. STA Pharmaceutical: Service Portfolio
  • Table 8.44. Sumitomo Chemical: Company Snapshot
  • Table 8.45. Sumitomo Chemical: Service Portfolio
  • Table 11.1. Oligonucleotide Synthesis: List of Partnerships and Collaborations, 2014-2023
  • Table 11.2. Partnerships and Collaborations: Information on Type of Oligonucleotide, Therapeutic Area and Application Area
  • Table 12.1. Oligonucleotide Synthesis: List of Recent Expansions
  • Table 13.1. Oligonucleotide Synthesis: List of Big Pharma Initiatives
  • Table 13.2. Big Pharma Initiatives: Information on Type of Oligonucleotide and Amount Invested
  • Table 14.1. Capacity Analysis: Information on Total Capacity (Sample Data Set)
  • Table 14.2. Capacity Analysis: Information on Average Capacity by Company Size (Sample Dataset)
  • Table 14.3. Global Installed Oligonucleotide Synthesis Capacity: Total Capacity by Company Size (mmol)
  • Table 15.1 Global Clinical Demand for Oligonucleotide Synthesis: Information on Number of Enrolled Patients and Trial Phase
  • Table 15.2 Global Commercial Demand for Oligonucleotide Synthesis: List of Oligonucleotide-based Products
  • Table 24.1. BianoGMP: Company Snapshots
  • Table 24.2. Hanugen Therapeutics: Company Snapshots
  • Table 24.3. IBA Life Sciences: Company Snapshots
  • Table 24.4. Axolabs: Company Snapshots
  • Table 24.5. SBS Genetech: Company Snapshots
  • Table 24.6. Aptagen: Company Snapshots
  • Table 24.7. Invitek Diagnostics: Company Snapshots
  • Table 28.1. Oligonucleotide Synthesis Providers: Distribution by Year of Establishment
  • Table 28.2. Oligonucleotide Synthesis Providers: Distribution by Company Size
  • Table 28.3. Oligonucleotide Synthesis Providers: Distribution by Location of Headquarters
  • Table 28.4. Oligonucleotide Synthesis Providers: Distribution by Company Size and Location of Headquarters
  • Table 28.5. Oligonucleotide Synthesis Providers: Distribution by Location of Oligonucleotide Synthesis Facilities
  • Table 28.6. Oligonucleotide Synthesis Providers: Distribution by Scale of Operation
  • Table 28.7. Oligonucleotide Synthesis Providers: Distribution by Type of Oligonucleotide Synthesized
  • Table 28.8. Oligonucleotide Synthesis Providers: Distribution by Type of Product Synthesized
  • Table 28.9. Oligonucleotide Synthesis Providers: Distribution by Application Area
  • Table 28.10. Oligonucleotide Synthesis Providers: Distribution by Type of Additional Services Offered
  • Table 28.11. Agilent Technologies: Annual Revenues, FY 2018-FY 2023 (USD Billion)
  • Table 28.12. Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2019-H1 FY 2023 (YEN Billion)
  • Table 28.13. Kaneka: Annual Revenues, FY 2019-Q1 FY 2023 (YEN Billion)
  • Table 28.14. LGC Group: Annual Revenues, FY 2019-FY 2023 (GBP Million)
  • Table 28.15. Merck: Annual Revenues, FY2019-9M FY 2023 (EUR Billion)
  • Table 28.16. Nitto Avecia: Annual Revenues, FY 2019-H1 FY 2023 (YEN Billion)
  • Table 28.17. Thermo Fisher Scientific: Annual Revenues, FY 2019-9M FY 2023 (USD Billion)
  • Table 28.18. Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2015-2023
  • Table 28.19. Clinical Trial Analysis: Distribution by Trial Status
  • Table 28.20. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2015-2023
  • Table 28.21. Clinical Trial Analysis: Distribution by Trial Phase
  • Table 28.22. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2007 - 2023
  • Table 28.23. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2015-2023
  • Table 28.24. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 28.25. Clinical Trial Analysis: Distribution by Type of Oligonucleotide
  • Table 28.26. Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 28.27. Clinical Trial Analysis: Distribution by Study Design
  • Table 28.28. Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 28.29. Most Active Players: Distribution by Number of Registered Trials
  • Table 28.30. Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Table 28.31. Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Table 28.32. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Table 28.33. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Table 28.34. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2023
  • Table 28.35. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 28.36. Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 28.37. Partnerships and Collaborations: Distribution by Type of Oligonucleotide
  • Table 28.38. Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 28.39. Partnerships and Collaborations: Distribution by Application Area
  • Table 28.40. Most Active Players: Distribution by Number of Partnerships
  • Table 28.41. Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 28.42. Partnerships and Collaborations: Local and International Agreements
  • Table 28.43. Recent Expansions: Cumulative Year-wise Trend, 2015-2023
  • Table 28.44. Recent Expansions: Distribution by Type of Expansion
  • Table 28.45. Recent Expansions: Distribution by Year and Type of Expansion
  • Table 28.46. Recent Expansions: Distribution by Location of Expanded Facility
  • Table 28.47. Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
  • Table 28.48. Recent Expansions: Distribution by Area of Expanded Facility (sq. ft.)
  • Table 28.49. Recent Expansions: Distribution by Scale of Operation
  • Table 28.50. Recent Expansions: Distribution by Amount Invested (USD Million)
  • Table 28.51. Most Active Players: Distribution by Number of Recent Expansions
  • Table 28.52. Big Pharma Players: Distribution by Number of Oligonucleotide related Initiatives
  • Table 28.53. Big Pharma Initiatives: Distribution by Year of Initiative, Pre-2020-2023
  • Table 28.54. Big Pharma Initiatives: Distribution by Type of Initiative
  • Table 28.55. Big Pharma Initiatives: Distribution by Type of Partnership
  • Table 28.56. Big Pharma Initiatives: Distribution by Type of Expansion
  • Table 28.57. Big Pharma Initiatives: Distribution by Year and Type of Initiative
  • Table 28.58. Big Pharma Initiatives: Distribution by Scale of Operation
  • Table 28.59. Big Pharma Initiatives: Distribution by Type of Oligonucleotide
  • Table 28.60. Big Pharma Initiatives: Distribution by Amount Invested (USD Million)
  • Table 28.61. Capacity Analysis: Distribution by Company Size
  • Table 28.62. Capacity Analysis: Distribution by Location of Synthesis Facility
  • Table 28.63. Distribution of Installed Oligonucleotide Synthesis Capacity in North America
  • Table 28.64. Distribution of Oligonucleotide Synthesis Capacity in Europe
  • Table 28.65. Distribution of Oligonucleotide Synthesis Capacity in Asia-Pacific and Rest of the World
  • Table 28.66. Overall Demand for Oligonucleotides, 2024-2035 (in kilograms)
  • Table 28.67. Global Clinical Demand for Oligonucleotides, 2024-2035 (in kilograms)
  • Table 28.68. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
  • Table 28.69. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
  • Table 28.70. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
  • Table 28.71. Global Commercial Demand for Oligonucleotides, 2024-2035 (in kilograms)
  • Table 28.72. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
  • Table 28.73. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
  • Table 28.74. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
  • Table 28.75. Global Oligonucleotide Synthesis Market, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.76. Global Oligonucleotide Synthesis Market, 2024-2035: Conservative Scenario (USD Billion)
  • Table 28.77. Oligonucleotide Synthesis Market, 2024-2035: Optimistic Scenario (USD Billion)
  • Table 28.78. Oligonucleotide Synthesis Market: Distribution by Application Area,2018, 2024 and 2035 (USD Billion)
  • Table 28.79. Oligonucleotide Synthesis Market for Research and Diagnostics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.80. Oligonucleotide Synthesis Market for Therapeutics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.81. Oligonucleotide Synthesis Market: Distribution by Type of Product Synthesized, 2018, 2024 and 2035 (USD Billion)
  • Table 28.82. Oligonucleotide Synthesis Market for Active Pharmaceutical Ingredients, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.83. Oligonucleotide Synthesis Market for Finished Dosage Forms, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.84. Oligonucleotide Synthesis Market: Distribution by Type of Oligonucleotide Synthesized, 2018, 2024 and 2035 (USD Billion)
  • Table 28.85. Oligonucleotide Synthesis Market for Antisense Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.86. Oligonucleotide Synthesis Market for DNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.87. Oligonucleotide Synthesis Market for siRNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.88. Oligonucleotide Synthesis Market for Other Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.89. Oligonucleotide Synthesis Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Billion)
  • Table 28.90. Oligonucleotide Synthesis Market for Commercial Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.91. Oligonucleotide Synthesis for Clinical Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.92. Oligonucleotide Synthesis Market: Distribution by Therapeutic Area, 2018, 2024 and 2035 (USD Billion)
  • Table 28.93. Oligonucleotide Synthesis Market for Rare Diseases, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.94. Oligonucleotide Synthesis Market for Liver Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.95. Oligonucleotide Synthesis Market for Genetic Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.96. Oligonucleotide Synthesis Market for Cardiovascular Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.97. Oligonucleotide Synthesis Market for Other Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.98. Oligonucleotide Synthesis Market: Distribution by End-users, 2018, 2024 and 2035 (USD Billion)
  • Table 28.99. Oligonucleotide Synthesis Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.100. Oligonucleotide Synthesis Market for Academic and Research Institutes, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.101. Oligonucleotide Synthesis Market for Hospitals, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.102. Oligonucleotide Synthesis Market: Distribution by Company Size, 2018, 2024 and 2035 (USD Billion)
  • Table 28.103. Oligonucleotide Synthesis Market for Large and Very Large Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.104. Oligonucleotide Synthesis Market for Mid-sized Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.105. Oligonucleotide Synthesis Market for Small Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.106. Oligonucleotide Synthesis Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Billion)
  • Table 28.107. Oligonucleotide Synthesis Market in North America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.108. Oligonucleotide Synthesis Market in the US, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.109. Oligonucleotide Synthesis Market in Canada, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.110. Oligonucleotide Synthesis Market in Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.111. Oligonucleotide Synthesis Market in Switzerland, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.112. Oligonucleotide Synthesis Market in Germany, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.113. Oligonucleotide Synthesis Market in Belgium, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.114. Oligonucleotide Synthesis Market in Rest of Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.115. Oligonucleotide Synthesis Market in Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.116. Oligonucleotide Synthesis Market in China, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
  • Table 28.117. Oligonucleotide Synthesis Market in South Korea, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
  • Table 28.118. Oligonucleotide Synthesis Market in Japan, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
  • Table 28.119. Oligonucleotide Synthesis Market in India, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
  • Table 28.120. Oligonucleotide Synthesis Market in Rest of Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Table 28.121. Oligonucleotide Synthesis Market in Rest of the World, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)

List of Figures

  • Figure 2.1 Research Methodology: Research Assumptions
  • Figure 2.2 Research Methodology: Project Methodology
  • Figure 2.3 Research Methodology: Forecast Methodology
  • Figure 2.4 Research Methodology: Robust Quality Control
  • Figure 2.5 Research Methodology: Key Market Segmentations
  • Figure 4.1. Executive Summary: Overall Market Landscape (I/II)
  • Figure 4.2. Executive Summary: Overall Market Landscape (II/II)
  • Figure 4.3. Executive Summary: Clinical Trial Analysis
  • Figure 4.4. Executive Summary: Partnerships and Collaborations
  • Figure 4.5. Executive Summary: Recent Expansions
  • Figure 4.6. Executive Summary: Big Pharma Initiatives
  • Figure 4.7. Executive Summary: Capacity Analysis
  • Figure 4.8. Executive Summary: Demand Analysis
  • Figure 4.9. Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 5.1. Classification of Oligonucleotides
  • Figure 5.2. Steps Involved in the Oligonucleotide Manufacturing
  • Figure 5.3. Types of Modifications of Oligonucleotides
  • Figure 5.4. Types of Purification Methods Used for Oligonucleotides
  • Figure 5.5. Commonly Outsourced Oligonucleotide Manufacturing Services
  • Figure 6.1. Oligonucleotide Synthesis Providers: Distribution by Year of Establishment
  • Figure 6.2. Oligonucleotide Synthesis Providers: Distribution by Company Size
  • Figure 6.3. Oligonucleotide Synthesis Providers: Distribution by Location of Headquarters
  • Figure 6.4. Oligonucleotide Synthesis Providers: Distribution by Company Size and Location of Headquarters
  • Figure 6.5. Oligonucleotide Synthesis Providers: Distribution by Location of Oligonucleotide Synthesis Facilities
  • Figure 6.6. Oligonucleotide Synthesis Providers: Distribution by Scale of Operation
  • Figure 6.7. Oligonucleotide Synthesis Providers: Distribution by Type of Oligonucleotide Synthesized
  • Figure 6.8. Oligonucleotide Synthesis Providers: Distribution by Type of Product Synthesized
  • Figure 6.9. Oligonucleotide Synthesis Providers: Distribution by Application Area
  • Figure 6.10. Oligonucleotide Synthesis Providers: Distribution by Type of Additional Services Offered
  • Figure 7.1. Company Competitiveness Analysis: Oligonucleotide Synthesis Providers based in North America
  • Figure 7.2. Company Competitiveness Analysis: Oligonucleotide Synthesis Providers based in Europe
  • Figure 7.3. Company Competitiveness Analysis: Oligonucleotide Synthesis Providers based in Asia-Pacific and Rest of the World
  • Figure 8.1. Agilent Technologies: Annual Revenues, FY 2018-FY 2023 (USD Billion)
  • Figure 8.2. Ajinomoto Bio-Pharma Services: Annual Revenues, FY 2019-H1 FY 2023 (YEN Billion)
  • Figure 8.3. Kaneka: Annual Revenues, FY2019-Q1 FY 2023 (YEN Billion)
  • Figure 8.4. LGC Group: Annual Revenues, FY 2019-FY 2023 (GBP Million)
  • Figure 8.5. Merck: Annual Revenues, FY2019-9M FY 2023 (EUR Billion)
  • Figure 8.6. Nitto Avecia: Annual Revenues, FY 2019-H1 FY 2023 (YEN Billion)
  • Figure 8.7. Thermo Fisher Scientific: Annual Revenues, FY 2019-9M FY 2023 (USD Billion)
  • Figure 9.1. Make versus Buy Decision Making Framework
  • Figure 9.2. Make versus Buy Decision Making: Possible Scenarios
  • Figure 10.1. Clinical Trial Analysis: Scope and Methodology
  • Figure 10.2. Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2015-2023
  • Figure 10.3. Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.4. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2015-2023
  • Figure 10.5. Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 10.6. Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2007 - post-2018
  • Figure 10.7. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2015-2023
  • Figure 10.8. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 10.9. Clinical Trial Analysis: Distribution by Type of Oligonucleotide
  • Figure 10.10. Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 10.11. Clinical Trial Analysis: Distribution by Study Design
  • Figure 10.12. Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 10.10. Most Active Players: Distribution by Number of Registered Trials
  • Figure 10.14. Clinical Trial Analysis: Distribution of Registered Trials by Geography
  • Figure 10.15. Clinical Trial Analysis: Distribution of Registered Trials by Trial Status and Geography
  • Figure 10.16. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Figure 10.17. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Figure 11.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2023
  • Figure 11.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 11.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 11.4. Partnerships and Collaborations: Distribution by Type of Oligonucleotide
  • Figure 11.5. Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 11.6. Partnerships and Collaborations: Distribution by Application Area
  • Figure 11.7. Most Active Players: Distribution by Number of Partnerships
  • Figure 11.8. Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 11.8. Partnerships and Collaborations: Local and International Agreements
  • Figure 12.1. Recent Expansions: Cumulative Year-wise Trend, 2015-2023
  • Figure 12.2. Recent Expansions: Distribution by Type of Expansion
  • Figure 12.3. Recent Expansions: Distribution by Year and Type of Expansion
  • Figure 12.4. Recent Expansions: Distribution by Location of Expanded Facility
  • Figure 12.5. Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
  • Figure 12.6. Recent Expansions: Distribution by Area of Expanded Facility (sq. ft.)
  • Figure 12.7. Recent Expansions: Distribution by Scale of Operation
  • Figure 12.8. Recent Expansions: Distribution by Amount Invested (USD Million)
  • Figure 12.9. Most Active Players: Distribution by Number of Recent Expansions
  • Figure 13.1. Big Pharma Initiatives: Distribution by Number of Initiatives
  • Figure 13.2. Big Pharma Initiatives: Distribution by Year of Initiative, Pre-2020-2023
  • Figure 13.3. Big Pharma Initiatives: Distribution by Type of Initiative
  • Figure 13.4. Big Pharma Initiatives: Distribution by Type of Partnership
  • Figure 13.5. Big Pharma Initiatives: Distribution by Type of Expansion
  • Figure 13.6. Big Pharma Initiatives: Distribution by Year and Type of Initiative
  • Figure 13.7. Big Pharma Initiatives: Distribution by Scale of Operation
  • Figure 13.8. Big Pharma Initiatives: Distribution by Type of Oligonucleotide
  • Figure 13.9. Big Pharma Initiatives: Distribution by Amount Invested (USD Million)
  • Figure 14.1. Capacity Analysis: Distribution by Company Size
  • Figure 14.2. Capacity Analysis: Distribution by Location of Synthesis Facility
  • Figure 14.3. Distribution of Oligonucleotide Synthesis Capacity in North America
  • Figure 14.4. Distribution of Oligonucleotide Synthesis Capacity in Europe
  • Figure 14.5. Distribution of Oligonucleotide Synthesis Capacity in Asia-Pacific and Rest of the World
  • Figure 15.1. Overall Demand for Oligonucleotides, 2024-2035 (in kilograms)
  • Figure 15.2. Global Clinical Demand for Oligonucleotides, 2024-2035 (in kilograms)
  • Figure 15.3. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
  • Figure 15.4. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
  • Figure 15.5. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
  • Figure 15.6. Global Commercial Demand for Oligonucleotides, 2024-2035 (in kilograms)
  • Figure 15.7. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
  • Figure 15.8. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
  • Figure 15.9. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
  • Figure 16.1. Oligonucleotide Synthesis: Market Drivers
  • Figure 16.2. Oligonucleotide Synthesis: Market Restraints
  • Figure 16.3. Oligonucleotide Synthesis: Market Opportunities
  • Figure 16.4. Oligonucleotide Synthesis: Market Challenges
  • Figure 17.1. Global Oligonucleotide Synthesis Market, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 17.2. Global Oligonucleotide Synthesis Market, 2024-2035: Conservative Scenario (USD Billion)
  • Figure 17.3. Oligonucleotide Synthesis Market, 2024-2035: Optimistic Scenario (USD Billion)
  • Figure 18.1. Oligonucleotide Synthesis Market: Distribution by Application Area, 2018, 2024 and 2035 (USD Billion)
  • Figure 18.2. Oligonucleotide Synthesis Market for Research and Diagnostics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 18.3. Oligonucleotide Synthesis Market for Therapeutics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 19.1. Oligonucleotide Synthesis Market: Distribution by Type of Product Synthesized, 2018, 2024 and 2035 (USD Billion)
  • Figure 19.2. Oligonucleotide Synthesis Market for Active Pharmaceutical Ingredients, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 19.3. Oligonucleotide Synthesis Market for Finished Dosage Forms, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 20.1. Oligonucleotide Synthesis Market: Distribution by Type of Oligonucleotide Synthesized, 2018, 2024 and 2035 (USD Billion)
  • Figure 20.2. Oligonucleotide Synthesis Market for Antisense Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 20.3. Oligonucleotide Synthesis Market for DNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 20.4. Oligonucleotide Synthesis Market for siRNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 20.5. Oligonucleotide Synthesis Market for Other Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 21.1. Oligonucleotide Synthesis Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Billion)
  • Figure 21.1. Oligonucleotide Synthesis Market for Commercial Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 21.2 Oligonucleotide Synthesis for Clinical Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 22.1. Oligonucleotide Synthesis Market: Distribution by Therapeutic Area, 2018, 2024 and 2035 (USD Billion)
  • Figure 22.2. Oligonucleotide Synthesis Market for Rare Diseases, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 22.3. Oligonucleotide Synthesis Market for Liver Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 22.4. Oligonucleotide Synthesis Market for Genetic Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 22.5. Oligonucleotide Synthesis Market for Cardiovascular Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 22.6. Oligonucleotide Synthesis Market for Other Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 23.1. Oligonucleotide Synthesis Market: Distribution by End-users, 2018, 2024 and 2035 (USD Billion)
  • Figure 23.2. Oligonucleotide Synthesis Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 23.3. Oligonucleotide Synthesis Market for Academic and Research Institutes, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 23.4. Oligonucleotide Synthesis Market for Hospitals, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 24.1. Oligonucleotide Synthesis Market: Distribution by Company Size, 2018, 2024 and 2035 (USD Billion)
  • Figure 24.2. Oligonucleotide Synthesis Market for Large and Very Large Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 24.3. Oligonucleotide Synthesis Market for Mid-sized Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 24.4. Oligonucleotide Synthesis Market for Small Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.1. Oligonucleotide Synthesis Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Billion)
  • Figure 25.2. Oligonucleotide Synthesis Market in North America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.3 Oligonucleotide Synthesis Market in the US, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.4 Oligonucleotide Synthesis Market in Canada, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.5. Oligonucleotide Synthesis Market in Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.6 Oligonucleotide Synthesis Market in Switzerland, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.7 Oligonucleotide Synthesis Market in Germany, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.8 Oligonucleotide Synthesis Market in Belgium, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.9. Oligonucleotide Synthesis Market in Rest of Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.10 Oligonucleotide Synthesis Market in Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.11 Oligonucleotide Synthesis Market in China, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
  • Figure 25.12 Oligonucleotide Synthesis Market in South Korea, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
  • Figure 25.13 Oligonucleotide Synthesis Market in Japan, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
  • Figure 25.14 Oligonucleotide Synthesis Market in India, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
  • Figure 25.15 Oligonucleotide Synthesis Market in Rest of Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 25.16 Oligonucleotide Synthesis Market in Rest of the World, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
  • Figure 27.1. Concluding Remarks: Oligonucleotide Synthesis: Overall Market Landscape
  • Figure 27.2. Concluding Remarks: Oligonucleotide Synthesis: Clinical Trial Analysis
  • Figure 27.3. Concluding Remarks: Oligonucleotide Synthesis: Partnerships and Collaborations
  • Figure 27.4. Concluding Remarks: Oligonucleotide Synthesis: Recent Expansions
  • Figure 27.5. Concluding Remarks: Oligonucleotide Synthesis: Big Pharma Initiatives
  • Figure 27.6. Concluding Remarks: Oligonucleotide Synthesis: Capacity Analysis
  • Figure 27.7. Concluding Remarks: Oligonucleotide Synthesis: Demand Analysis
  • Figure 27.8. Concluding Remarks: Oligonucleotide Synthesis: Market Sizing and Opportunity Analysis (I/II)
  • Figure 27.9. Concluding Remarks: Oligonucleotide Synthesis: Market Sizing and Opportunity Analysis (II/II)